Items related to Drugs in Cancer Care
The treatment of cancer has undergone dramatic evolutions in the past two decades and the provision of holistic care by a multidisciplinary team of specialists is emerging as the cornerstone of recent improvements in outcome. Accompanying this multidisciplinary approach is the increasing complexity of therapeutic agents and modalities utilized.
Drugs in Cancer Care is a succinct, practical and user-friendly guide to commonly used drugs and non-surgical therapeutic modalities in oncology. This detailed yet concise handbook contains over 90 monographs of cancer care providing the information needed to deliver chemotherapy with safety and precision, including information on mechanism of action, clinical pharmacology, side effect profile, tumour indications, combination treatment and how to respond to the hepato-renal impairment seen in many patients with advanced cancer.
In an easy to use A-Z format this handbook will appeal to a variety of healthcare professional involved in the provision of cancer care and medicine information and will become an essential and well-thumbed item in every oncologist's toolkit.
Drugs in Cancer Care is a succinct, practical and user-friendly guide to commonly used drugs and non-surgical therapeutic modalities in oncology. This detailed yet concise handbook contains over 90 monographs of cancer care providing the information needed to deliver chemotherapy with safety and precision, including information on mechanism of action, clinical pharmacology, side effect profile, tumour indications, combination treatment and how to respond to the hepato-renal impairment seen in many patients with advanced cancer.
In an easy to use A-Z format this handbook will appeal to a variety of healthcare professional involved in the provision of cancer care and medicine information and will become an essential and well-thumbed item in every oncologist's toolkit.
"synopsis" may belong to another edition of this title.
About the Author:
Rachel Midgley, Consultant Oncologist and DH/HEFCE Clinical Senior Lecturer, Director of the Oncology Clinical Trials Office (OCTO) Churchill Hospital and the University of Oxford Churchill Campus, Oxford, UK,Mark R. Middleton, Professor of Experimental Cancer Medicine and Consultant Medical Oncologist, Oxford University Hospitals NHS Trust, Oxford, UK,Andrew Dickman, Consultant pharmacist, Palliative care Blackpool Teaching Hospitals NHS Foundation Trust and Marie Curie Palliative Care Institute Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Cancer Research Centre, UK,David Kerr, Professor of Cancer Medicine, University of Oxford, UK and Adjunct Professor of Medicine, Weill-Cornell College of Medicine, New York, USA
Rachel Midgley studied Medicine at the University of Birmingham (1988-1994) and gained a first class Honours in an intercalated BSc in Physiology. After completing general medical training as an SHO in Birmingham and completing the Membership of the Royal College of Physicians, she was awarded a competitive MRC Personal Fellowship to carry out research towards her PhD in Cancer Studies, while commencing oncology training. Rachel presently works as a Consultant in Medical Oncology and Senior Lecturer in Cancer Studies at the Churchill Hospital in
Oxford and the University of Oxford. She is Director of the Oncology Clinical Trials Office at the University and oversees all the Cancer Trials activity. She has assisted in attracting grants totalling more than L7M and authored over 50 publications in cancer research. Her main focus of research is in the adjuvant treatment of colorectal cancer; identifying new agents for use and defining novel prognostic and predictive markers in this setting.
Mark Middleton is Professor of Experimental Cancer Medicine at the University of Oxford and a Medical Oncologist at the Oxford Cancer and Haematology Centre. His oncology training was at the Christie Hospital and the Paterson Institute for Cancer Research, Manchester, where his PhD was on Strategies to Enhance the Efficacy of Alkylating Agent Chemotherapy. His clinical interests are in cancer drug development and in the treatment of melanoma.
Current work focuses on the genetic characterisation of patients and their melanoma, the potential for signal transduction inhibitors to modulate DNA repair and on the ability of agents affecting chromatin to potentiate cytotoxic chemotherapy. Mark is a member of the National Cancer Research Institute Melanoma Clinical Studies Group, leading several clinical trials in the UK national portfolio, and having responsibility for their translational research delivery.
David Kerr has made sustained and internationally recognised contribution to cancer care and research in the field of drug development over the past 3 decades. He has published over 300 papers in high profile journals, authored over twenty books, and has been awarded 4 prestigious, international research prizes, including the NHS's first Nye Bevan award for Innovation. His scientific standing has been recognised by election as Fellow of Academy of Medical Sciences in 2000, President of the European society of Medical Oncology (2009-2011) and Founding Fellow of the European Academy of Cancer Sciences (2010). He has also completed the "Kerr Report" (2006), a 20 year plan to reform Scotland's NHS - a root and branch review of every aspect of the NHS and organised the first ever African Cancer Reform convention in London (2007).
Andrew Dickman is a Consultant Pharmacist at the Blackpool Victoria Hospital and Marie Curie Hospice in Liverpool. He is also a project lead at the Marie Curie Palliative Care Institute, University of Liverpool. Andrew is the co-author several books, including the Syringe Driver, the Palliative Care Formulary (PCF2) and Chronic Pain, part of the Oxford Pain Management Library. He has also contributed chapters to several books, including the Care of the Dying, Wall and Melzack's Textbook of Pain and Palliative Medicine. His job involves clinical work, research and education and he is currently undertaking a Doctorate in Pharmacy Practice.
Rachel Midgley, Consultant Oncologist and DH/HEFCE Clinical Senior Lecturer, Director of the Oncology Clinical Trials Office (OCTO) Churchill Hospital and the University of Oxford Churchill Campus, Oxford, UK,Mark R. Middleton, Professor of Experimental Cancer Medicine and Consultant Medical Oncologist, Oxford University Hospitals NHS Trust, Oxford, UK,Andrew Dickman, Consultant pharmacist, Palliative care Blackpool Teaching Hospitals NHS Foundation Trust and Marie Curie Palliative Care Institute Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Cancer Research Centre, UK,David Kerr, Professor of Cancer Medicine, University of Oxford, UK and Adjunct Professor of Medicine, Weill-Cornell College of Medicine, New York, USA
Rachel Midgley studied Medicine at the University of Birmingham (1988-1994) and gained a first class Honours in an intercalated BSc in Physiology. After completing general medical training as an SHO in Birmingham and completing the Membership of the Royal College of Physicians, she was awarded a competitive MRC Personal Fellowship to carry out research towards her PhD in Cancer Studies, while commencing oncology training. Rachel presently works as a Consultant in Medical Oncology and Senior Lecturer in Cancer Studies at the Churchill Hospital in
Oxford and the University of Oxford. She is Director of the Oncology Clinical Trials Office at the University and oversees all the Cancer Trials activity. She has assisted in attracting grants totalling more than L7M and authored over 50 publications in cancer research. Her main focus of research is in the adjuvant treatment of colorectal cancer; identifying new agents for use and defining novel prognostic and predictive markers in this setting.
Mark Middleton is Professor of Experimental Cancer Medicine at the University of Oxford and a Medical Oncologist at the Oxford Cancer and Haematology Centre. His oncology training was at the Christie Hospital and the Paterson Institute for Cancer Research, Manchester, where his PhD was on Strategies to Enhance the Efficacy of Alkylating Agent Chemotherapy. His clinical interests are in cancer drug development and in the treatment of melanoma.
Current work focuses on the genetic characterisation of patients and their melanoma, the potential for signal transduction inhibitors to modulate DNA repair and on the ability of agents affecting chromatin to potentiate cytotoxic chemotherapy. Mark is a member of the National Cancer Research Institute Melanoma Clinical Studies Group, leading several clinical trials in the UK national portfolio, and having responsibility for their translational research delivery.
David Kerr has made sustained and internationally recognised contribution to cancer care and research in the field of drug development over the past 3 decades. He has published over 300 papers in high profile journals, authored over twenty books, and has been awarded 4 prestigious, international research prizes, including the NHS's first Nye Bevan award for Innovation. His scientific standing has been recognised by election as Fellow of Academy of Medical Sciences in 2000, President of the European society of Medical Oncology (2009-2011) and Founding Fellow of the European Academy of Cancer Sciences (2010). He has also completed the "Kerr Report" (2006), a 20 year plan to reform Scotland's NHS - a root and branch review of every aspect of the NHS and organised the first ever African Cancer Reform convention in London (2007).
Andrew Dickman is a Consultant Pharmacist at the Blackpool Victoria Hospital and Marie Curie Hospice in Liverpool. He is also a project lead at the Marie Curie Palliative Care Institute, University of Liverpool. Andrew is the co-author several books, including the Syringe Driver, the Palliative Care Formulary (PCF2) and Chronic Pain, part of the Oxford Pain Management Library. He has also contributed chapters to several books, including the Care of the Dying, Wall and Melzack's Textbook of Pain and Palliative Medicine. His job involves clinical work, research and education and he is currently undertaking a Doctorate in Pharmacy Practice.
"About this title" may belong to another edition of this title.
- PublisherOxford University Press
- Publication date2013
- ISBN 10 0199664579
- ISBN 13 9780199664573
- BindingPaperback
- Edition number1
- Number of pages288
- EditorMidgley Rachel, Middleton Mark R., Dickman Andrew, Kerr David
Buy New
Learn more about this copy
US$ 78.15
Shipping:
US$ 11.05
From United Kingdom to U.S.A.
Top Search Results from the AbeBooks Marketplace
Stock Image
Drugs in Cancer Care
Published by
Oxford University Press
(2013)
ISBN 10: 0199664579
ISBN 13: 9780199664573
New
Paperback / softback
Quantity: 5
Seller:
Rating
Book Description Paperback / softback. Condition: New. New copy - Usually dispatched within 4 working days. Providing an overview of pharmacology and prescribing advice, Drugs in Cancer Care contains over 90 drug monographs, presented in easy-to-use and accessbile A-Z format. This detailed yet concise handbook is ideal for all healthcare professionals involved in the provision of cancer care. Seller Inventory # B9780199664573
Buy New
US$ 78.15
Convert currency
Stock Image
Drugs in Cancer Care
Published by
Oxford Univ Pr
(2013)
ISBN 10: 0199664579
ISBN 13: 9780199664573
New
Paperback
Quantity: 1
Seller:
Rating
Book Description Paperback. Condition: Brand New. 1st edition. 241 pages. 7.00x4.00x0.50 inches. In Stock. Seller Inventory # zk0199664579
Buy New
US$ 105.41
Convert currency
Stock Image
Drugs in Cancer Care
Published by
Oxford University Press
(2013)
ISBN 10: 0199664579
ISBN 13: 9780199664573
New
Softcover
Quantity: 1
Seller:
Rating
Book Description Condition: New. Buy with confidence! Book is in new, never-used condition. Seller Inventory # bk0199664579xvz189zvxnew
Buy New
US$ 127.15
Convert currency